pentobarbital will decrease the extent or outcome of linagliptin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Use of other remedies is strongly advisable when linagliptin is to be administered which has a CYP3A4 inducerpentobarbital will reduce the extent or effect of buprenorphine subdermal implant by affecting hepa